. Author manuscript; available in PMC: 2014 Feb 1.

Published in final edited form as: Mayo Clin Proc. 2013 Feb;88(2):10.1016/j.mayocp.2012.11.007. doi: 10.1016/j.mayocp.2012.11.007

TABLE 2.

Bleeding Outcomes

Characteristic	Patient group^a		P value	RR (95% CI)^b
Characteristic	Clopidogrel (n=40)	Control (n=80)	P value	RR (95% CI)^b
Hemoglobin values
Nadir, g/dL	9.1 (1.2)	9.0 (1.1)	.64
Delta, g/dL	3.0 (1.7)	3.5 (1.6)	.08
Delta >4 g/dL	11 (28)	25 (31)	.67	0.88 (0.48-1.60)
Major bleeding event	2 (5)	3 (4)	1.00	1.33 (0.23-7.66)
Combined bleeding outcome	19 (48)	36 (45)	.80	1.06 (0.70-1.58)
pRBCs
Total units	2.1 (2.1)	2.1 (3.5)	.49
Patients requiring >3 units	9 (23)	14 (18)	.51	1.29 (0.61-2.71)
Total units of platelets	0 (0)	0.1 (0.5)	.32
Total units of FFP	0 (0)	0.5 (1.9)	.04
Vitamin K during hospitalization	0 (0)	12 (15)	.008	NR

cryo = cryoprecipitate; FFP = fresh frozen plasma; pRBCs = packed red blood cells; RR = relative risk.

Values are mean (SD) or No. of patients (%).

RR only provided for categorical data.

NR: Relative risk not reported since no patient in the clopidogrel group received vitamin K during hospitalization